Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21755391 | 0.93 | ESR2 (0.40) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL4492789 | 0.85 | ESR2 (0.52) | ESR2ESR1MMP2MMP9OPRD1 | |
| Phenol SCHEMBL4491407 | 0.78 | CA12 (0.48) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL1495106 | 0.77 | ESR2 (0.54) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL5241008 | 0.77 | ESR2 (0.60) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL1516123 | 0.75 | ESR2 (0.61) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL23977378 | 0.74 | ESR2 (0.49) | ESR2ESR1 | |
| SCHEMBL19486880 | 0.72 | ESR2 (0.43) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL3682201 | 0.72 | ESR2 (0.39) | ESR2ESR1MMP2MMP9OPRD1 | |
| SCHEMBL25276644 | 0.71 | TSHR (0.39) | SCN10AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340155-A1 | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation | CU Ventures, Inc. | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340155-A1 | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation | ESR2, GPER1, ESR1 | ESR2 1/4885ESR1 3/4885MMP2 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.